System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Guillaume Piessen is an expert in Surgery at Hôpital Claude Huriez (France). As of October 2026, ScienceLeadR ranks Guillaume Piessen in the top 1% of experts worldwide for Esophageal Neoplasms, Esophageal Diseases and Gastrointestinal Neoplasms. Guillaume Piessen has authored 513 publications, the most recent in 2026, and is an investigator in 56 clinical trials, 14 of them ongoing. SLR score: 2,158 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Guillaume Piessen Hôpital Claude Huriez France
2 158 ScienceLeadR Reputation 2158

Unlock

Register Login
Network Map

Surgery

Subspecialties: Oncology - Gastroenterology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2005 - 2026
Source: PubMed

Hôpital Claude Huriez

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 513

Citations

Citations: 14 645 1st author: 28 Last author: 53 Unique author: 2

Main journals

Ann Surg 47
J Clin Oncol 38
Ann Surg Oncol 36
Eur J Surg Oncol 25
Ann Oncol 24

Best Journals

J Clin Oncol 26
Ann Oncol 16
Lancet Oncol 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
International expert consensus on the management of paraconduit herniation after esophagectomy: results of a two-round Delphi survey.
PMID 42773263 — neoplasms, sutures, work, esophagectomy		Surg Endosc20260
The Impact of Anastomotic Leak After Esophagectomy on Long-term Survival in the Modern Era of Management (ALES Study): A Multicenter Cohort Study.
PMID 42687130 — cohort studies, anastomotic leak, esophagectomy, general surgery		Ann Surg20260
Standard reporting on duodenal stump leakage after gastric cancer resections: multicentre analysis from the GASTRODATA Study Group (the STARDUST study).
PMID 42678183 — registries, blood transfusion, mortality, blood, neoplasms, cohort studies, weight loss, therapeutics, gastrectomy, general surgery, stomach neoplasms, prognosis		Br J Surg20260
Preoperative High-Dose Corticosteroids in Digestive Cancer Surgery: A Randomized Clinical Trial.
PMID 42616512 — methylprednisolone, intraabdominal infections, surgical procedures, operative, adrenal cortex hormones, neoplasms, wound infection, infections, postoperative complications		JAMA Surg20261
The Prognostic Impact of Lymph Node Yield Upon Survival in Esophageal Cancer Broken Down by Neoadjuvant Strategy: A Multicenter European Cohort Study.
PMID 42533309 — mortality, lymph nodes, lymph node excision, neoplasms, cohort studies, lymph, neoadjuvant therapy, therapeutics, esophageal neoplasms, esophagectomy, general surgery		Ann Surg20260

Clinical Studies 56

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 16 Study Director: 1

By phase:

N/A 30
Phase 3 14
Phase 2 10
Phase 2/Phase 3 2

By status:

Completed 23
Recruiting 17
Unknown 6
Active not recruiting 4
Terminated 4
Not yet recruiting 2

By type:

Interventional 40
Observational 16

By Monocentric/Multicentric:

monocentric 20
multicentric2to4 1
multicentric5to9 4
multicentricup10 31

Main Topics

Cohort/Consortium Investigators 19

Ongoing Clinical Trials

14 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
PRODIGE 88 CIRCULATE PAC Phase III multicentric open label randomized study to investigate the efficacy of chemotherapy in patients with positive ctDNA after surgery and adjuvant chemotherapy for a high risk stage II and stage III Colorectal Cancer
2023-505046-26-00 — neoplasms, colon, drug therapy, chemotherapy, adjuvant, colorectal neoplasms, chemotherapy, carcinoma		Phase 3Recruiting2026
A Study of Barrett s Esophagus Patients Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer
NCT07455422 — cells, quality of life, disclosure, fear, disease-free survival, blood, gastroenterology, esophagus, neoplasms, adenocarcinoma, biopsy, cell biology, barrett esophagus, tissues, dna, dissection, endoscopic mucosal resection, cytology		N/ANot yet recruiting2026
Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer
NCT07408999 — thoracotomy, stomach, esophagus, celiac artery, lymph node excision, esophagogastric junction, thoracic duct, neoplasms, hepatic artery, arteries, lymph, robotic surgical procedures, morbidity, gastric artery, therapeutics, esophageal neoplasms, esophagectomy, splenic artery		N/ANot yet recruiting2026
Risk adapted adjuvant chemotherapy guided by the tumour stage for operated pancreatic adenocarcinoma following neoadjuvant chemotherapy with FOLFIRINOX FRENCH26 PRODIGE93 PANACHE02 Trial
2024-519048-33-00 — adenocarcinoma, drug therapy, chemotherapy, adjuvant, therapeutics, chemotherapy		Phase 2/Phase 3Recruiting2025
A Study of Barrett s Esophagus Patients to Investigate Quality of Life and Fear of Cancer and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer
NCT06523374 — cells, quality of life, pilots, fear, blood, esophagus, neoplasms, adenocarcinoma, cohort studies, biopsy, biomarkers, cell biology, endoscopy, barrett esophagus, esophageal neoplasms, tissues, cytology		N/ARecruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS